Oragenics Inc is a biotechnology company focused on the development of innovative solutions for infectious diseases and oral health
The company is primarily engaged in creating novel antibiotics and therapeutics, particularly against multi-drug resistant pathogens, as well as products aimed at enhancing oral health through advanced microbial therapies. Oragenics leverages its proprietary technologies and research capabilities to address significant medical needs, with a mission to improve patient outcomes and combat rising antibiotic resistance through targeted and effective treatment options.
Oragenics (NYSE American: OGEN) announced its participation at the Emergencies in Medicine Conference, where Chief Medical Officer Dr. James Kelly presented on advancements in concussion treatment. His session focused on Oragenics’ “Trigger-to-Treat” program and the development of ONP-002, an intranasal neurosteroid designed for acute concussion care. The presentation also highlighted the integration of BRAINBox Solutions’ multi-marker diagnostic platform in clinical trials to enhance concussion detection and prognosis. Oragenics aims to establish a new standard for early intervention and precise treatment strategies, contributing to improved patient outcomes in concussion management.
Oragenics (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, announced that its Chief Medical Officer Dr James Kelly has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury and Brain Health. The appointment reflects Dr Kelly’s pioneering work, including his previous leadership at the National Intrepid Center of Excellence at Walter Reed National Military Medical Center, and reinforces the foundation’s mission to support research, raise awareness and drive actionable solutions for brain injury care. Janet Huffman, Interim Chief Executive Officer and Chief Financial Officer of Oragenics, noted the move bolsters the company’s commitment to developing its novel intranasal treatment for concussion, ONP-002, while Leigh Steinberg welcomed Dr Kelly’s expertise in transforming concussion treatment. Dr Kelly said he is honored to join the Medical Board and dedicated to advancing innovative treatment options to improve patient outcomes.
Oragenics (NYSE American: OGEN) announced a strategic collaboration with BRAINBox Solutions to develop an integrated diagnostic and treatment platform for mild traumatic brain injury (mTBI). The partnership will combine BRAINBox’s AI-driven diagnostic technology with Oragenics’ intranasal therapeutic candidate, ONP-002, aimed at mitigating brain injury effects and promoting recovery. The initiative seeks to establish a seamless “trigger-to-treat” system, enhancing early diagnosis and personalized treatment. With over 5 million concussions occurring annually in the U.S., the companies aim to set a new standard in TBI management.
Oragenics (NYSE American: OGEN) announced that its Chief Medical Officer, Dr. James P. Kelly, will be a featured panelist at the 12th Annual Brain Health Summit on Feb. 8, 2025, in New Orleans. The event, hosted by sports agent Leigh Steinberg, focuses on concussion awareness and treatment advancements. Dr. Kelly, a leading expert in neurology, will discuss innovative approaches to traumatic brain injury (TBI) care, including Oragenics’ intranasal neurosteroid, ONP-002. The summit gathers medical professionals, athletes, and industry leaders to drive progress in brain health and injury prevention.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Oragenics (NYSE American: OGEN), a biotechnology company focused on brain health treatments, reported strategic progress following its $4 million capital raise in September 2024. The company has enhanced ONP-002’s intranasal formulation and device, finalized Phase II trial preparations in Australia, and completed prototyping for automated delivery to aid patients with altered consciousness. Oragenics plans to dose the first Australian patient in Phase II trials by early Q2 2025 and submit an investigational new drug (IND) package for U.S. Phase IIb trials by Q3 2025. Interim CEO Janet Huffman, a seasoned executive with expertise in financial leadership and strategic growth, steps into her role with a commitment to advancing the company’s mission and building shareholder value. The Board praised Huffman’s leadership as Oragenics continues to innovate and address unmet medical needs.
Oragenics (NYSE American: OGEN) has converted its remaining Series A and Series B Preferred Shares into common stock, simplifying its capital structure and eliminating approximately $2.35 million in liquidation preference. The conversion retired 5,417,000 Series A and 4,050,000 Series B Preferred Shares, resulting in the issuance of roughly 22,000 common shares. CFO Janet Huffman emphasized that this move removes a significant stock overhang, strengthens the company’s financial foundation, and supports its mission to advance innovative treatments for neurological and rare diseases.
Oragenics (NYSE American: OGEN), a company specializing in brain-related health treatments, will present at the Centurion One Capital 2nd Annual Bahamas Summit on Oct. 22-23, 2024. President Michael Redmond will deliver a corporate presentation and participate in a Q&A session at 1:20 p.m. ET on Oct. 22 at the Rosewood Baha Mar Hotel in Nassau, Bahamas.
Oragenics (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, has released a corporate update. Highlights of shareholder report include an overview of key milestones reached this year as the company has developed its lead candidate, ONP-002, a first-in-class neurosteroid designed for the treatment of concussions. Those milestones include strengthening the company’s clinical leadership, preparing for a phase 2 clinical trial, successful cardiotoxicity testing and required genotoxicity studies and establishing a key partnership with Avance Clinical, a leading contract research organization (“CRO”).
Oragenics completed a key study showing its nasal spray drug ONP-002 effectively targets brain-related nasal areas, setting the stage for Phase 2 trials in concussion treatment.
Oragenics Inc. (NYSE American: OGEN) has successfully completed a key FDA-recognized study for its concussion treatment drug, ONP-002. Delivered via a nasal spray, ONP-002 demonstrated the ability to target areas within the nose directly linked to the brain, increasing the likelihood of reaching the brain quickly after an injury. The study, utilizing an FDA-approved intranasal casting model, paves the way for Phase II trials where ONP-002 will be administered to concussion patients within eight hours of injury. Oragenics’ breakthrough aims to fill the unmet need for pharmaceutical treatment in concussion care.
Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced the closing of its previously announced public offering. The offering consisted of 3,078,378 shares of the company’s common stock at an offering price of $0.55 per unit and pre-funded warrants to purchase up to 5,028,206 shares of common stock at $0.549 per unit. The offering raised approximately $4.45 million in gross proceeds before deductions, with the company planning to use the net proceeds to fund the continued development of its ONP-002 product candidate and for general corporate purposes and working capital. Dawson James Securities, Inc. acted as the sole placement agent for the offering.
